Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, sec-disclosure
TL;DR
Keros Therapeutics filed an 8-K on 6/6/25. Standard corporate update.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Keros Therapeutics is providing updated corporate and financial information to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- June 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39264 (company_id) — Commission File Number
- 81-1173868 (ein) — I.R.S. Employer Identification No.
- 1050 Waltham Street, Suite 302 (address) — Principal executive offices street
- Lexington (city) — Principal executive offices city
- Massachusetts (state) — Principal executive offices state
- 02421 (zip_code) — Principal executive offices zip code
- ( 617 ) 314-6297 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated June 6, 2025.
What is the full legal name of the company filing this report?
The full legal name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Keros Therapeutics, Inc.?
The Commission File Number for Keros Therapeutics, Inc. is 001-39264.
What is the principal executive office address of Keros Therapeutics, Inc.?
The principal executive office address is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Keros Therapeutics, Inc. (KROS).